Showing results (381-390 of 393) with videos related to

Sort By:
Pageof 40
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Localized colon cancer, version 3.2013: featured updates to the NCCN GuidelinesAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in OncologyAl B Benson, Alan P Venook, Lynette Cederquist, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Colon cancer, version 3.2014Al B Benson, Alan P Venook, Tanios Bekaii-Saab, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2013
Metastatic colon cancer, version 3.2013: featured updates to the NCCN GuidelinesAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Rectal Cancer, Version 2.2015Al B Benson, Alan P Venook, Tanios Bekaii-Saab, et al.
Neurology|May 10, 2006
APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answersR M Burwick, P P Ramsay, J L Haines, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 19, 2019
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Pageof 40